Brief: Xencor Collaborates with Janssen to Discover Novel CD28 Bispecific Antibodies for Treatment of Prostate Cancer

Xencor

07/12/2020 13:25

Dec 7 (Reuters) - Xencor Inc  XNCR.O :
    * XENCOR ENTERS COLLABORATION WITH JANSSEN WITH AIM TO
DISCOVER
NOVEL CD28 BISPECIFIC ANTIBODIES FOR THE TREATMENT OF PROSTATE
CANCER
    * XENCOR INC - RECEIVES $50 MILLION UPFRONT PAYMENT,
ELIGIBLE TO
RECEIVE POTENTIAL MILESTONE PAYMENTS & ROYALTY ON NET SALES FROM
COMMERCIALIZED MEDICINES
    * XENCOR - EACH CO GETS RIGHT TO CONDUCT DIRECTED
NON-REGISTRATIONAL CLINICAL STUDIES IN PROSTATE CANCER,
COMBINING ITS AGENTS WITH THAT FROM OTHER'S PORTFOLIO
    * XENCOR - TO APPLY XMAB BISPECIFIC FC TECHNOLOGY TO CREATE,
CHARACTERIZE XMAB CD28 BISPECIFIC ANTIBODY CANDIDATES AGAINST
TUMOR TARGET SPECIFIED BY JANSSEN

Source text for Eikon:  ID:nBwbSfywXa 
Further company coverage:  XNCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))